drugset
drugset / Trial / NCT02874664

A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer

NCT02874664 ↗

Phase 1 Completed 46 enrolled Stemcentrx
NaSingle-groupOpen-labelTreatment

Summary

Study to evaluate the effect of rovalpituzumab tesirine on cardiac ventricular repolarization in subjects with small cell lung cancer (SCLC).

Timeline

Start
2016-09
Primary completion
2018-09-12
Completion
2018-09-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rovalpituzumab tesirine Other / unclassified 0.3 mg/kg Intravenous

Indications

small cell lung carcinoma